Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$78.2 million.

  • Ascendis Pharma A's Interest Expenses fell 18097.74% to -$78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 9572.31%. This contributed to the annual value of $108.3 million for FY2024, which is 12834.86% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Interest Expenses stood at -$78.2 million, which was down 18097.74% from $37.4 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Interest Expenses ranged from a high of $83.8 million in Q1 2024 and a low of -$78.2 million during Q3 2025
  • For the 5-year period, Ascendis Pharma A's Interest Expenses averaged around $14.4 million, with its median value being $10.2 million (2023).
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 2210937.59% in 2023, then crashed by 20429.14% in 2024.
  • Ascendis Pharma A's Interest Expenses (Quarter) stood at -$447292.7 in 2021, then rose by 29.75% to -$314236.2 in 2022, then soared by 22109.38% to $69.2 million in 2023, then plummeted by 100.02% to -$13891.7 in 2024, then plummeted by 562928.56% to -$78.2 million in 2025.
  • Its Interest Expenses was -$78.2 million in Q3 2025, compared to $37.4 million in Q2 2025 and $47.1 million in Q1 2025.